Abstract
In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.
| Original language | English |
|---|---|
| Pages (from-to) | 457-460 |
| Number of pages | 4 |
| Journal | European Journal of Clinical Pharmacology |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 1987 |
Fingerprint
Keywords
- adverse effect
- bromoergocriptine
- domperidone
- dopamine
- prolactin
- puerperal hyperprolactinaemia
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)
Cite this
Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women. / Nappi, C.; Colace, G.; Di Renzo, G. F.; Taglialatela, M.; Amoroso, S.; Annunziato, L.; Montemagno, U.
In: European Journal of Clinical Pharmacology, Vol. 32, No. 5, 09.1987, p. 457-460.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women
AU - Nappi, C.
AU - Colace, G.
AU - Di Renzo, G. F.
AU - Taglialatela, M.
AU - Amoroso, S.
AU - Annunziato, L.
AU - Montemagno, U.
PY - 1987/9
Y1 - 1987/9
N2 - In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.
AB - In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.
KW - adverse effect
KW - bromoergocriptine
KW - domperidone
KW - dopamine
KW - prolactin
KW - puerperal hyperprolactinaemia
UR - http://www.scopus.com/inward/record.url?scp=0023181376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023181376&partnerID=8YFLogxK
U2 - 10.1007/BF00637669
DO - 10.1007/BF00637669
M3 - Article
C2 - 3622595
AN - SCOPUS:0023181376
VL - 32
SP - 457
EP - 460
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
SN - 0031-6970
IS - 5
ER -